Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1 8Phase 3 6Phase 1/2 2Phase NA 1Phase 2/3 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1Hematologic Neoplasms 1Graft vs Host Disease 1

Interventions

Cisplatin 22Fluorouracil 21Radiotherapy 18Gemcitabine 17Docetaxel 16Oxaliplatin 15Paclitaxel 14Carboplatin 13Capecitabine 13Bevacizumab 13Leucovorin 11Cyclophosphamide 11Irinotecan 10Drug Therapy 10Cytarabine 9Saline Solution 7Magnetic Resonance Spectroscopy 7Letrozole 7Dexamethasone 7Rituximab 6Nivolumab 6Methotrexate 6Exercise 6Etoposide 6Electroporation 6Doxorubicin 6pembrolizumab 5Pemetrexed 5Metformin 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × peginterferon alfa-2b × Clear all
NCT02634294 2023-03-16

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2/3 Completed
30 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡